Research programme: Hsp90 heat shock protein inhibitors - Merck Serono/Merck KGaAAlternative Names: EMD 683671; Hsp90 inhibitors - Merck Serono Research/Merck KGaA
Latest Information Update: 25 Oct 2016
At a glance
- Originator Merck KGaA; Merck Serono
- Class Indazoles; Resorcinols; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Sep 2010 Preclinical development is ongoing in Germany
- 04 Sep 2008 Preclinical trials in Cancer in Germany (PO)